Citations

Clear

2285 citation(s) found for "Yu, Anthony".

Radial Neck–to–Humerus Transposition for Elbow Reconstruction Following Oncologic Resection of the Proximal Ulna
Houdek, Matthew T. , Gupta, Sanjay , Griffin, Anthony M. , Wunder, Jay S. , Ferguson, Peter C. , Houdek, Matthew T

Mayo Clinic

JBJS Case Connector | November 4, 2019 | Volume: 9 | Issue: 4 | Pages: e0451-e0451

10.2106/jbjs.cc.18.00451 | PMID 31688060 Get It

Case: Two young adult (aged 25 and 21 years) patients presented with sarcomas of the proximal ulna. To achieve an oncological margin, the proximal ulna required resection. Owing to the complex biomechanics of the elbow joint, reconstructive options are limited and have a high complication rate. The elbow was reconstructed with a transposition of the radial neck to the trochlea of the humerus in both patients. At over 2 years of follow-up, both patients have a stable and functional elbow. Conclusions: Transposition of the radial neck to the trochlea of the humerus provides a biological reconstruction in this complex problem.
Acute Kidney Injury in Patients Undergoing Cardiac Transplantation: A Meta-Analysis
Lertjitbanjong, Ploypin , Crisafio, Anthony , Mao, Michael A. , Watthanasuntorn, Kanramon , Aeddula, Narothama Reddy , Cheungpasitporn, Wisit , Kaewput, Wisit , Crisafio, Anthony , Mao, Michael A , Aeddula, Narothama Reddy , Kaewput, Wisit , Cheungpasitporn, Wisit , Thongprayoon, Charat , Hansrivijit, Panupong

Mayo Clinic

Medicines | November 1, 2019 | Volume: 6 | Issue: 4 | Pages: 108

10.3390/medicines6040108 | PMID 31683875 Get It

Background: Acute kidney injury (AKI) is a common complication following solid-organ transplantation. However, the epidemiology of AKI and mortality risk of AKI among patients undergoing cardiac transplantation is not uniformly described. We conducted this study to assess the incidence of AKI and mortality risk of AKI in adult patients after cardiac transplantation. Methods: A systematic review of EMBASE, MEDLINE, and Cochrane Databases was performed until June 2019 to identify studies evaluating the incidence of AKI (by standard AKI definitions), AKI requiring renal replacement therapy (RRT), and mortality risk of AKI in patients undergoing cardiac transplantation. Pooled AKI incidence and mortality risk from the included studies were consolidated by random-effects model. The protocol for this study is registered with PROSPERO (no. CRD42019134577). Results: 27 cohort studies with 137,201 patients undergoing cardiac transplantation were identified. Pooled estimated incidence of AKI and AKI requiring RRT was 47.1% (95% CI: 37.6–56.7%) and 11.8% (95% CI: 7.2–18.8%), respectively. The pooled ORs of hospital mortality and/or 90-day mortality among patients undergoing cardiac transplantation with AKI and AKI requiring RRT were 3.46 (95% CI, 2.40–4.97) and 13.05 (95% CI, 6.89–24.70), respectively. The pooled ORs of 1-year mortality among patients with AKI and AKI requiring RRT were 2.26 (95% CI, 1.56–3.26) and 3.89 (95% CI, 2.49–6.08), respectively. Conclusion: Among patients undergoing cardiac transplantation, the incidence of AKI and severe AKI requiring RRT are 47.1% and 11.8%, respectively. AKI post cardiac transplantation is associated with reduced short term and 1-year patient survival.
Performance and Return to Sport After Anterior Cruciate Ligament Reconstruction in Professional Baseball Players
Chalmers, Peter N. , D’Angelo, John , Ma, Kevin , Dahm, Diane L., Erickson, Brandon J. , Romeo, Anthony A. , Ahmad, Christopher S.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | October 30, 2019 | Volume: 7 | Issue: 10 | Pages: No page available

10.1177/2325967119878431 | PMID 31696134 Get It

Background: Anterior cruciate ligament reconstruction (ACLR) is the gold standard treatment for ACL tears to allow baseball players to return to sport (RTS). The optimal graft type and femoral tunnel drilling technique are currently unknown. Hypothesis: There is a high rate of RTS in professional baseball players after ACLR, with no significant difference in RTS rates or performance between cases and controls or between graft types or femoral drilling techniques. Study Design: Cohort study; Level of evidence, 3. Methods: All professional baseball players who underwent ACLR between 2010 and 2015 were included. Demographic and performance data (pre- and postoperative) for each player were recorded. Performance metrics were then compared between cases and matched controls. Results: A total of 124 players (mean age, 23.7 ± 4.1 years; 83% minor league players) underwent ACLR. Of these, 80% returned to sport (73% to the same or higher level) at a mean 310 ± 109 days overall and 333 ± 126 days at the same or higher level. The most common graft type was an ipsilateral bone–patellar tendon–bone (BTB) autograft (n = 87; 70%). A total of 91 players underwent concomitant meniscal debridement or repair. No significant difference in any of the primary performance metrics existed from before to after ACLR. Compared with matched controls, no significant difference existed in RTS rates or any performance metrics after ACLR. No significant difference existed in RTS rates or primary performance outcome measures between graft types or femoral drilling techniques. Conclusion: The RTS rate for professional baseball players after ACLR was 80%. No significant difference in performance metrics existed between BTB and hamstring autografts or between femoral drilling techniques. Furthermore, no significant difference in performance or RTS rates existed between cases and matched controls. Femoral drilling technique and graft type did not affect performance and RTS rates in professional baseball players after ACLR.
Effect of incremental increase in radial neck height on coronoid and capitellar contact pressures
Ramazanian, Taghi , Müller-Lebschi, Julia A., Chuang, Min-Yao , Vaichinger, Anthony M. , Fitzsimmons, James S. , O’Driscoll, Shawn W. , Fitzsimmons, James S

Mayo Clinic

Shoulder & Elbow | October 30, 2019 | Volume: 13 | Issue: 4 | Pages: 445-450

10.1177/1758573219881772 | PMID 34394742 Get It

Background Over-lengthening of the radial neck has been shown to affect ulnohumeral kinematics and has been proposed to affect radiocapitellar pressures. We hypothesized that an incremental increase in radial neck height increases the capitellar contact pressure and reduces the coronoid contact pressure. Knowledge of the effects of over-lengthening is clinically important in preventing pain and degenerative changes due to overstuffing. Methods Six human cadaveric elbows were prepared on a custom-designed apparatus simulating muscle loads and passive flexion from 0° to 90° under gravity valgus torque while measuring joint contact pressures in this biomechanical study. Each elbow was tested sequentially starting with the intact specimen followed by insertion of a radial head prosthesis with 0, +2, and +4 mm of radial neck height, respectively. Results Capitellar mean contact pressures significantly increased after insertion of +2 and +4 mm radial head prostheses (p < 0.03). The capitellar mean contact pressure with a 0 mm radial head prosthesis was 97 KPa. Insertion of +2 mm and +4 mm radial heads increased mean contact pressures to 391 KPa (p = 0.001) and 619 KPa (p = 0.001), respectively, with 90° of elbow flexion. Discussion Increasing radial prosthesis height by 2 mm significantly increases capitellar contact pressures and reduces coronoid contact pressures.
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
Gralow, Julie R. , Barlow, William E. , Paterson, Alexander , Lew, Danika L., Stopeck, Alison , Hayes, Daniel F. , Hershman, Dawn L. , Schubert, Mark M., Clemons, Mark , Poznak, Catherine Van , Dees, Elizabeth Claire , Messino, Michael J., Margolis, Jeffrey, Dakhil, Shaker R. , Chew, Helen K. , Dammann, Kim Z, Abrams, Jeffrey S. , Livingston, Robert B., Ingle, James N. , Hershman, Dawn L , Gralow, Julie R , Barlow, William E , Miao, Jieling , Falkson, Carla I. , Elias, Anthony , Hortobágyi, Gabriel N.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 28, 2019 | Volume: 112 | Issue: 7 | Pages: 698-707

10.1093/jnci/djz215 | PMID 31693129 Get It

Abstract Background Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines include recommendations for adjuvant bisphosphonates in postmenopausal patients. SWOG/Alliance/Canadian Cancer Trials Group/ECOG-ACRIN/NRG Oncology study S0307 compared the efficacy of three bisphosphonates in early-stage breast cancer. Methods Patients with stage I–III breast cancer were randomly assigned to 3 years of intravenous zoledronic acid, oral clodronate, or oral ibandronate. The primary endpoint was disease-free survival (DFS) with overall survival as a secondary outcome. All statistical tests were two-sided. Results A total of 6097 patients enrolled. Median age was 52.7 years. Prior to being randomly assigned, 73.2% patients indicated preference for oral vs intravenous formulation. DFS did not differ across arms in a log-rank test (P = .49); 5-year DFS was 88.3% (zoledronic acid: 95% confidence interval [CI] = 86.9% to 89.6%), 87.6% (clodronate: 95% CI = 86.1% to 88.9%), and 87.4% (ibandronate: 95% CI = 85.6% to 88.9%). Additionally, 5-year overall survival did not differ between arms (log rank P = .50) and was 92.6% (zoledronic acid: 95% CI = 91.4% to 93.6%), 92.4% (clodronate: 95% CI = 91.2% to 93.5%), and 92.9% (ibandronate: 95% CI = 91.5% to 94.1%). Bone as first site of recurrence did not differ between arms (P = .93). Analyses based on age and tumor subtypes showed no treatment differences. Grade 3/4 toxicity was 8.8% (zoledronic acid), 8.3% (clodronate), and 10.5% (ibandronate). Osteonecrosis of the jaw was highest for zoledronic acid (1.26%) compared with clodronate (0.36%) and ibandronate (0.77%). Conclusions We found no evidence of differences in efficacy by type of bisphosphonate, either in overall analysis or subgroups. Despite an increased rate of osteonecrosis of the jaw with zoledronic acid, overall toxicity grade differed little across arms. Given that patients expressed preference for oral formulation, efforts to make oral agents available in the United States should be considered.
148. Retrospective Evaluation of Acute Cholangitis and Clinical Implication and Management of Secondary Bacteremia
Hamdi, Ahmed , Miller, Alexander T. , Diaz, Mark Anthony , Yetmar, Zachary A. , Fida, Madiha , Beam, Elena

Mayo Clinic

Open Forum Infectious Diseases | October 23, 2019 | Volume: 6 | Issue: Supplement_2 | Pages: S101-S101

10.1093/ofid/ofz360.223 Get It

Abstract Background Optimum duration of antimicrobial therapy for acute bacteremic cholangitis is not well established; however, 4–7 days is recommended by the 2018 Tokyo guidelines in those without Gram-positive bacteremia. Methods A retrospective study performed at Mayo Clinic - Rochester, Florida and Arizona sites was conducted, reviewing all adult patients with the first episode of acute cholangitis secondary to biliary stone obstruction, between January 1, 2012 and December 31, 2017. We reviewed the duration of prescribed antimicrobials. Results Among 331 included cases, 197(60%) were men, 66 (20%) were immuno-compromised. Presenting symptoms included fever in 202 (61.5%), abdominal pain in 289 (87%), jaundice 128(38.7%), and altered mentation in 49 (15%). Among these, 256 (77%) were classified as “definite” and 38 (11.5%) were “suspected” using the 2018 Tokyo guideline classification. Cholangitis grade was grade III in 134 (40.5%); grade II in 115 (34.7%); and grade I in 82 (24.8%). Majority of cases, 321 (97%), underwent source control—most commonly 309 (96%) achieved by endoscopic retrograde cholangiopancreatography (ERCP). Source control occurred within 24 hr of presentation in 197 (61.4%) of the cases. Bacteremia was documented in 131/277 (47%). Majority of bacteremias were due to Gram-negative organisms in 119 (91%). Mean duration of antibiotic therapy following “source control” was 9.6 days (SD 7.0). Cases with bacteremia, resulted in longer treatment duration, mean of 13 days (SD 5.6), regardless of the isolated organism. Overall 30 day mortality was 14/331 (4.2%). No mortality difference was noted in patients who underwent early (within 12 hours) vs. later source control (4.55% Vs. 4.53%), nor in those who received more or less than 6 days of antibiotic therapy after source control (4.7% Vs. 3.9%, P = 0.76). No difference in mortality was observed in those with or without bacteremia. Conclusion Our results note the use of longer courses of antimicrobials for management of bacteremic cholangitis, regardless of the organism type. This population could be a prime target for an antimicrobial stewardship intervention, to decrease the duration of prescribed antimicrobials in accordance with recent guidelines. Disclosures All authors: No reported disclosures.
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Gökbuget, Nicola , Kantarjian, Hagop M. , Brüggemann, Monika , Stein, Anthony S. , Bargou, Ralf C. , Dombret, Hervé , Heffner, Leonard T., Rigal‐Huguet, Françoise , Litzow, Mark R. , Gao, Shan , Nagorsen, Dirk , Forman, Stephen J. , Topp, Max S. , Kantarjian, Hagop , Fielding, Adele K. , O’Brien, Susan , Zugmaier, Gerhard

Mayo Clinic

Blood Advances | October 21, 2019 | Volume: 3 | Issue: 20 | Pages: 3033-3037

10.1182/bloodadvances.2019000457 | PMID 31648325 Get It

Key Points MRD response has value as a prognostic factor for blinatumomab treatment in R/R B-cell precursor ALL. MRD response was associated with better outcomes in terms of OS and RFS in blinatumomab-treated R/R ALL.
Teriparatide treatment increases Hounsfield units in the lumbar spine out of proportion to DEXA changes
Mikula, Anthony L. , Puffer, Ross C. , Jeor, Jeffery D. St. , Bernatz, James T. , Fogelson, Jeremy L. , Sebastian, Arjun S. , Freedman, Brett A. , Currier, Bradford L. , Bydon, Mohamad , Yaszemski, Michael J. , Anderson, Paul A. , Elder, Benjamin D. , Larson, A. Noelle , Nassr, Ahmad

Mayo Clinic

Journal of Neurosurgery: Spine | October 19, 2019 | Volume: 32 | Issue: 1 | Pages: 50-55

10.3171/2019.7.spine19654 | PMID 31628287 Get It

OBJECTIVEThe authors sought to assess whether Hounsfield units (HU) increase following teriparatide treatment and to compare HU increases with changes in bone mineral density (BMD) as measured by dual-energy x-ray absorptiometry (DEXA).METHODSA retrospective chart review was performed from 1997 to 2018 across all campuses at our institution. The authors identified patients who had been treated with at least 6 months of teriparatide and compared HU and BMD as measured on DEXA scans before and after treatment.RESULTSFifty-two patients were identified for analysis (46 women and 6 men, average age 67 years) who underwent an average of 20.9 ± 6.5 months of teriparatide therapy. The mean ± standard deviation HU increase throughout the lumbar spine (L1–4) was from 109.8 ± 53 to 133.9 ± 61 HU (+22%, 95% CI 1.2–46, p value = 0.039). Based on DEXA results, lumbar spine BMD increased from 0.85 to 0.93 g/cm2 (+9%, p value = 0.044). Lumbar spine T-scores improved from −2.4 ± 1.5 to −1.7 ± 1.5 (p value = 0.03). Average femoral neck T-scores improved from −2.5 ± 1.1 to −2.3 ± 1.0 (p value = 0.31).CONCLUSIONSTeriparatide treatment increased both HU and BMD on DEXA in the lumbar spine, without a change in femoral BMD. The 22% improvement in HU surpassed the 9% improvement determined with DEXA. These results support some surgeons’ subjective sense that intraoperative bone quality following teriparatide treatment is better than indicated by DEXA results. To the authors’ knowledge, this is the first study demonstrating an increase in HU with teriparatide treatment.